|
Comparing Two Treatment Regimens for Helicobacter pylori Eradication: Furazolidone or Clarithromycin?
|
Shirin Rezaei1    , Abdollah Pooshani2 , Sima Besharat3 , Mehrangiz Pichak4 , Alireza Norouzi *5 |
1- Internal Medicine, Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran.
2- Gastroenterology and Liver Specialist, Clinical Research Development Unit (CRDU), Golestan University of Medical Sciences, Gorgan, Iran.
3- Associate Professor of Biomedical Sciences (By Research), Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran.
4- General Physician, Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran.
5- Associate Professor of Gastroenterology and Hepatology, Clinical Research Development Unit (CRDU), Golestan University of Medical Sciences, Gorgan, Iran. University of Queensland Faculty of Medicine, and Princess Alexandra Hospital Department of Gastroenterology and Hepatology Brisbane Queensland Australia. , norouzi54@gmail.com |
|
|
Abstract: (403 Views) |
Background and Objective: Clarithromycin-based quadruple treatment is a common treatment regimen for Helicobacter pylori (H. pylori) eradication in Iran. However, its success rate has been unsatisfactory in recent years due to increasing antibiotic resistance. This study aimed to compare the two treatment regimens, i.e., furazolidone and clarithromycin, for H. pylori eradication.
Methods: This descriptive-analytical retrospective study was conducted on the medical records of 100 symptomatic patients (54 females and 46 males; mean age=45.86±11.97 years) confirmed with H. pylori infection via urea breath test (UBT) or rapid urease test (RUT), who presented to Shahid Sayyad Shirazi Educational-Therapeutic Center in Gorgan, Iran, for endoscopy during 2019. Patients had been treated for two weeks with one of two routine oral quadruple drug regimens based on furazolidone and clarithromycin. The first quadruple drug regimen included bismuth subnitrate 240 mg twice daily, clarithromycin 500 mg twice daily, omeprazole 20 mg once daily, and amoxicillin 1000 mg twice daily. The second quadruple drug regimen involved bismuth subnitrate 240 mg twice daily, furazolidone 200 mg twice daily, omeprazole 20 mg once daily, and amoxicillin 1000 mg twice daily. H. pylori eradication rates were determined using a stool antigen test in patients who completed the entire course of treatment (four weeks after the end of the treatment regimen).
Results: The eradication rates for the furazolidone-based and clarithromycin-based quadruple regimens were determined to be 98% and 94%, respectively, showing no statistically significant difference. The odds ratio for H. pylori eradication was not statistically significantly associated with age, gender, or treatment regimen type.
Conclusion: Both two-week furazolidone-based and clarithromycin-based quadruple regimens were effective in eradicating H. pylori, with neither regimen demonstrating superiority over the other. |
|
Keywords: Helicobacter pylori [MeSH], Clarithromycin [MeSH], Furazolidone [MeSH], Peptic Ulcer [MeSH], Dyspepsia [MeSH]
Article ID: Vol27-15 |
|
|
Full-Text [PDF 438 kb]
(286 Downloads)
| | Abstract (HTML) (6 Views)
|
|
Type of Study: Original Articles |
Subject:
Gastroenterology
|
|
|
|
|
|
|
| References |
1. Hajaghamohammadi A, Safiabadi Tali SH, Samimi R, Oveisi S, Kazemifar AM. Low dose furazolidone for eradication of H- pylori instead of clarithromycin: a clinical trial. Glob J Health Sci. 2014 Aug;7(1):235-39. https://doi.org/10.5539/gjhs.v7n1p235. [ DOI] [ PubMed] 2. Alavinejad P, Seiedian S, Ebadi Borna K, Hajiani E, Lajmirnia M, Hesam S. Comparison of Furazolidone Versus Clarithromycin for Eradication of Helicobacter Pylori Infection: A Randomized Multicenter Clinical Trial. AJIED. 2021;11(1):44-50. https://dx.doi.org/10.21608/aeji.2021.50347.1117. [ Link] [ DOI] 3. Chey WD, Mégraud F, Laine L, López LJ, Hunt BJ, Howden CW. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial. Gastroenterology. 2022 Sep;163(3):608-19. https://doi.org/10.1053/j.gastro.2022.05.055. [ DOI] [ PubMed] 4. Abangah G, Raughani A, Asadollahi P, Asadollahi K. Comparison between the two drug regimens of PPI+Amoxicillin+ Rifampicin and PPI+Amoxicillin+ Levofloxacin for the treatment of H. pylori infections resistant to the first line drug regimen among patients referred to Ilam clinics. Gastroenterol Hepatol Bed Bench. 2019;12(3):209-16. [ PubMed] 5. Yi DM, Yang TT, Chao SH, Li YX, Zhou YL, Zhang HH, et al. Comparison the cost-efficacy of furazolidone-based versus clarithromycin-based quadruple therapy in initial treatment of Helicobacter pylori infection in a variable clarithromycin drug-resistant region, a single-center, prospective, randomized, open-label study. Medicine (Baltimore). 2019 Feb;98(6):e14408. https://doi.org/10.1097/md.0000000000014408. [ DOI] [ PubMed] 6. Fakheri H, Saberi Firoozi M, Bari Z. Eradication of Helicobacter Pylori in Iran: A Review. Middle East J Dig Dis. 2018 Jan;10(1):5-17. https://doi.org/10.15171/mejdd.2017.84. [ DOI] [ PubMed] 7. Gholinia N, Shafikhani AA, Hajiaghamohammadi A. Comparing Regimens Based on Clarithromycin, Furazolidone, and Levofloxacin in Patients With Helicobacter Pylori Infection: A Clinical Trial. Int J Enteric Pathog. 2021;9(1): 15-20. https://doi.org/10.34172/ijep.2021.04. [ Link] [ DOI] 8. Keikha M, Askari P, Ghazvini K, Karbalaei M. Levofloxacin-based therapy as an efficient alternative for eradicating Helicobacter pylori infection in Iran: a systematic review and meta-analysis. J Glob Antimicrob Resist. 2022 Jun;29:420-29. https://doi.org/10.1016/j.jgar.2021.10.019. [ DOI] [ PubMed] 9. Bakhshipour A, Mohsenpour Mohammadi N, Hashemi SM, Momeni MK. Comparison of Clarithromycin-based Triple Therapy and Furazolidone-based Quadruple Therapy in Eradicating Helicobacter pylori Infection. Int J Infect. 2021;8(1):e98954. https://doi.org/10.5812/iji.98954. [ Link] [ DOI] 10. Shirzad-Aski H, Besharat S, Kienesberger S, Sohrabi A, Roshandel G, Amiriani T, et al. Association Between Helicobacter pylori Colonization and Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2021 May-Jun;55(5):380-92. https://doi.org/10.1097/mcg.0000000000001415. [ DOI] [ PubMed] 11. Isapanah Amlashi F, Ashkbari A, Amiriani T, Norouzi A, Poorkhani AH, Sedaghat SM, et al. Primary Liver Cancer in Golestan Province, Northeastern Iran: 13-Year Experience of Golestan Population-Based Cancer Registry (GPCR). Arch Iran Med. 2021 Oct; 24(10):727-32. https://doi.org/10.34172/aim.2021.107. [ DOI] [ PubMed] 12. Lee YC, Dore MP, Graham DY. Diagnosis and Treatment of Helicobacter pylori Infection. Annu Rev Med. 2022;73:183-95. https://doi.org/10.1146/annurev-med-042220-020814. [ Link] [ DOI] 13. Qiao C, Li Y, Liu J, Ji C, Qu J, Hu J, et al. Clarithromycin versus furazolidone for naïve Helicobacter pylori infected patients in a high clarithromycin resistance area. J Gastroenterol Hepatol. 2021 Sep;36(9):2383-88. https://doi.org/10.1111/jgh.15468. [ DOI] [ PubMed] 14. Garza-González E, Perez-Perez GI, Maldonado-Garza HJ, Bosques-Padilla FJ. A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication. World J Gastroenterol. 2014 Feb; 20(6):1438-49. https://doi.org/10.3748/wjg.v20.i6.1438. [ DOI] [ PubMed] 15. Siavoshi F, Saniee P, Latifi-Navid S, Massarrat S, Sheykholeslami A. Increase in resistance rates of H. pylori isolates to metronidazole and tetracycline--comparison of three 3-year studies. Arch Iran Med. 2010 May;13(3):177-87. [ PubMed] 16. Talebi Bezmin Abadi A, Ghasemzadeh A, Taghvaei T, Mobarez AM. Primary resistance of Helicobacter pylori to levofloxacin and moxifloxacine in Iran. Intern Emerg Med. 2012 Oct;7(5):447-52. https://doi.org/10.1007/s11739-011-0563-1. [ DOI] [ PubMed] 17. Rahmani A, Jafari A, Mabrokzadeh H, Asadollahi K, Abangah G, Sayemiri K, et al. Comparison between the effectiveness of Furazolidone and Clarithromycin on eradication of helicobacter pylori among patients with peptic ulcer. J Basic Res Med Sci. 2015;2(4):45-50. [ Link] 18. Pourfarzi F, Zahirian Moghadam T, Zandian H, Malekzadeh R, Yazdanbod A. Cost-effectiveness analysis of two routine therapeutic methods for Helicobacter pylori eradication: a Persian cohort-based study. Gastroenterol Hepatol Bed Bench. 2021;14(3):250-59. [ PubMed] |
|
| Send email to the article author |
|
|
|
Rezaei S, Pooshani A, Besharat S, Pichak M, Norouzi A. Comparing Two Treatment Regimens for Helicobacter pylori Eradication: Furazolidone or Clarithromycin?. J Gorgan Univ Med Sci 2025; 27 (2) :42-49 URL: http://goums.ac.ir/journal/article-1-4544-en.html
|
